Lv2
182 积分 2024-01-22 加入
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes
8天前
已完结
Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience
2个月前
已完结
Bladder Preservation Therapy: A Review of the Literature and Future Directions
2个月前
已完结
Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future
2个月前
已完结
Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer
2个月前
已完结
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
2个月前
已完结
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2个月前
已完结
746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
2个月前
已完结
EE154 Budget Impact Analysis of Pembrolizumab Plus Enfortumab Vedotin As First-Line Treatment of Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma in USA
2个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
2个月前
已完结
皖公网安备34019202002308
